(via TheNewswire)
- Q3 Milestones achieved as scheduled, including 3D imaging reconstruction software implementation, mechanical and electrical design, and clinical study design
- IzoView engineering update
- Meetings with Starfish Medical
Q3 2021 Milestones
1.3D Imaging Reconstruction Software Implementation
An initial software demonstration has been presented to management and engineering teams and is progressing on schedule to be integrated into the initial IzoView clinical study units.
2.Electro-mechanical Designs
The mechanical, electrical, and control systems designs have been completed as scheduled. The Bill of Materials (a complete list of parts required to build the systems) has been completed, and the key components have been sourced and are on site. Additional customized electro-mechanical parts are currently being fabricated.
3.Clinical Study Design Finalized
IzoView Engineering Update
With electrical and mechanical designs completed, the fabrication of IzoView is now underway and ahead of schedule.
Under the leadership ofDr. Younes Achkire, VP of Product Engineering,
“Great progress has been made on all engineering aspects. Izotropic’s engineering teams are moving the focus to industrial design and designing for manufacturability. I am considering all manufacturing processes and lead times and feel confident that testing of IzoView can begin with initial phantom13D reconstructions in Q1 2022 as projected,” said Dr. Achkire.
Meetings with Starfish Medical
Izotropic’s management and engineering teams took advantage of recent changes in provincial and international COVID-19 travel restrictions and organized in-person meetings at Starfish Medical based in
The Company will share highlights from the visit to Starfish Medical on itssocial media channelsandwebsitein the coming weeks.
ON BEHALF OF THE COMPANY
Dr.
For investor relations inquiries, contact:
Email:jberard@izocorp.com
Cell: 778-228-2314
Toll Free: 1-833-IZOCORP ext.1
About
More information about
Forward-Looking Statements
This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the Company’s management, business, and its knowledge of the relevant market and economic environment in which it operates. The Company has tried, where possible, toidentify such information and statements by using words such as “anticipate,” “believe,” “envision,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such, they may cause future results of the Company’s activity to differ significantly from the content and implications of such statements. Forward-Looking Statements are pertinent only as of the date on which they are made, and the Company undertakes no obligation to update or revise any Forward-Looking Statements to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law. Neither the Company nor its shareholders, officers, and consultants, shall be liable for any action and the results of any action taken by any person based on the information contained herein, including without limitation the purchase or sale of Company securities. Nothing in this document should be deemed to be medical or other advice of any kind.
1Phantoms are objects that stand in for human tissue to confirm the device is operating correctly.
Copyright (c) 2021 TheNewswire - All rights reserved.
Copyright (c) 2021 TheNewswire - All rights reserved., source